John C. Byrd

Medicine · The Ohio State University

Established · publishing since 1995Rising activity

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Immunodeficiency and Autoimmune Disorders Acute Lymphoblastic Leukemia research Monoclonal and Polyclonal Antibodies Research

Publications

201

Citations

17,299

Est. group size

—

Recurring co-author estimate

Active years

Publishing since 1995

Research summary

AI-generated

John C. Byrd's research focuses on blood cancers, particularly chronic lymphocytic leukemia (CLL) and lymphoma, examining new drug treatments, side effects of therapies, and biological markers that help predict patient outcomes. His work often involves large clinical trials and studies of how factors like age and disease genetics affect treatment response. This research is relevant to students interested in clinical and translational cancer research, especially in blood-related cancers.

Chronic lymphocytic leukemia (CLL)Lymphoma biology and treatmentCancer drug toxicity and safetyMolecular and genetic markers in cancerClinical trials in hematologic malignancies

Publication output was fairly steady from 2017 to 2020, dropped to zero in 2021-2022, then resumed at a lower and more variable pace through 2023-2025.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence

Publications per year over the last 10 years — averaging 2.0/year recently

Recent publications

Comprehensive comparison of enzymatic and bisulfite DNA methylation analysis in clinically relevant samples
Clinical Epigenetics · 2025
ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
Journal of Clinical Oncology · 2019
Genetic heterogeneity of diffuse large B-cell lymphoma
UNC Libraries · 2019
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)
Journal of Geriatric Oncology · 2018
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis
British Journal of Haematology · 2018
Toxicities and Related Outcomes of Elderly Patients (pts) (≥65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611)
Blood · 2016
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma
Blood · 2016

Publishes in

Blood×5
British Journal of Haematology×3
UNC Libraries×3
Oncotarget×2
Leukemia & lymphoma/Leukemia and lymphoma×2

Similar researchers

By research-topic overlap

Michael R. Grever
Medicine · The Ohio State University
Margaret S. Lucas
Medicine · The Ohio State University
Kerry A. Rogers
Medicine · The Ohio State University
Mollie E. Moran
Medicine · The Ohio State University
Jennifer A. Woyach
Medicine · The Ohio State University

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 19, 2026.

Claim or correct this profile